

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

Assignment ID: PATI651014

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
SAVID THERAPEUTICS INC.	11/22/2024
<b>RECEIVING PARTY DATA</b>	
<b>Company Name:</b>	CompleCure, Inc.
<b>Street Address:</b>	1-12-8, Shibuya, Shibuya-ku
<b>City:</b>	TOKYO
<b>State/Country:</b>	JAPAN
<b>Postal Code:</b>	150-0002
<b>PROPERTY NUMBERS Total: 3</b>	
<b>Property Type</b>	<b>Number</b>
<b>Patent Number:</b>	9670255
<b>Patent Number:</b>	11286285
<b>Patent Number:</b>	11161884
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	7037161180
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	7037161191
<b>Email:</b>	gbpatent@gbpatent.com,yfujinosadowski@gbpatent.com
<b>Correspondent Name:</b>	Ryan Chirnomas
<b>Address Line 1:</b>	1950 ROLAND CLARKE PLACE
<b>Address Line 4:</b>	RESTON, VIRGINIA 20191
<b>ATTORNEY DOCKET NUMBER:</b>	J204944
<b>NAME OF SUBMITTER:</b>	Yuka Fujino Sadowski
<b>SIGNATURE:</b>	Yuka Fujino Sadowski
<b>DATE SIGNED:</b>	11/22/2024
<b>Total Attachments: 3</b>	
source=P48132_P50788_P56604_Executed Assignment#page1.tiff	
source=P48132_P50788_P56604_Executed Assignment#page2.tiff	
source=P48132_P50788_P56604_Executed Assignment#page3.tiff	

ASSIGNMENT

WHEREAS, **SAVID THERAPEUTICS INC.**, a corporation organized and existing under the laws of JAPAN, whose mailing address is 3-9-10, Eifuku, Suginami-ku, Tokyo 168-0064, JAPAN, hereinafter referred to as the ASSIGNOR, is the sole owner of the patent applications and Letters Patents listed in the attached Appendix.

AND WHEREAS, **CompleCure, Inc.**, a corporation organized and existing under the laws of Japan, whose mailing address is 1-12-8, Shibuya, Shibuya-ku, Tokyo 150-0002, JAPAN, hereinafter known as the ASSIGNEE, is desirous of acquiring ASSIGNOR's entire right, title and interest for the United States in and to said invention and application, including any and all divisionals and continuations thereof, and any and all Letters Patent which may be granted thereon, including any and all renewals, reissues, reexaminations, and prolongations thereof.

NOW, THIS WITNESSETH that for good and valuable consideration, the receipt whereof is hereby acknowledged, said ASSIGNOR hereby assigns, sells and transfers to said ASSIGNEE, its assigns and legal representatives, the ASSIGNOR's entire and exclusive right, title and interest in and to said invention and application, for the United States including any and all divisionals and continuations thereof, and any and all Letters Patent which may be granted therefor and all rights to sue for past and future infringement thereunder, said ASSIGNEE and its assigns and legal representatives to have, hold, exercise and enjoy the said invention and application, including any and all divisionals and continuations thereof, and any and all Letters Patent which may be granted thereon, including any and all renewals, reissues, reexaminations, and prolongations thereof, with all the rights, powers, privileges, and advantages in any ways arising from or pertaining thereto, for and during the term or terms of any and all such Letters Patent when granted, including any and all renewals, reissues, reexaminations, and prolongations thereof, for the use and benefit of said ASSIGNEE and its assigns and legal representatives in as ample and beneficial a manner to all intents and purposes as the said ASSIGNOR might or could have held and enjoyed the same, if this assignment had not been made.

AND said ASSIGNOR hereby agrees to execute all papers necessary to file applications in the United States for said invention and to assign the same to said ASSIGNEE, or any assignee acquiring title to said invention, and to execute any other papers that may be needed in connection with filing said application and securing Letters Patent thereon.

AND said ASSIGNOR authorizes and requests the Commissioner of Patents to issue Letters Patent on said application, and on any and all divisionals and continuations thereof, to said ASSIGNEE, its assigns and legal representatives, in accordance herewith.


IN TESTIMONY WHEREOF, this assignment is executed by said ASSIGNOR, on the date indicated below.

First Witness (optional):

\_\_\_\_\_  
(Name)

\_\_\_\_\_  
(Date)

SAVID THERAPEUTICS INC.



Signature

Masanobu TSUKAGOSHI

Name

Chief Executive Officer

Title

Nov. 22, 2024

Date

Second Witness (optional):

\_\_\_\_\_  
(Name)

\_\_\_\_\_  
(Date)

**APPENDIX****U.S. Patents**

<b>Title</b>	<b>Application No.</b>	<b>Filing Date</b>	<b>Patent No.</b>	<b>Issue Date</b>
MODIFIED BIOTIN, MUTANT STREPTAVIDIN, AND USE THEREOF	14/768,916	08/19/2015	9,670,255	06/06/2017
MODIFIED BIOTIN, STREPTAVIDIN MUTANT, AND USAGE OF THEM	15/119,441	08/17/2016	11,286,285	03/29/2022
MODIFIED BIOTIN, STREPTAVIDIN MUTANT, AND USAGE OF THEM	16/512,894	07/16/2019	11,161,884	11/02/2021

{J204944 06262255.DOC}